NO20052914D0 - Terapeutiske forbindelser - Google Patents
Terapeutiske forbindelserInfo
- Publication number
- NO20052914D0 NO20052914D0 NO20052914A NO20052914A NO20052914D0 NO 20052914 D0 NO20052914 D0 NO 20052914D0 NO 20052914 A NO20052914 A NO 20052914A NO 20052914 A NO20052914 A NO 20052914A NO 20052914 D0 NO20052914 D0 NO 20052914D0
- Authority
- NO
- Norway
- Prior art keywords
- therapeutic compounds
- therapeutic
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0229931.1A GB0229931D0 (en) | 2002-12-21 | 2002-12-21 | Therapeutic agents |
| PCT/GB2003/005602 WO2004056748A1 (en) | 2002-12-21 | 2003-12-19 | Therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052914D0 true NO20052914D0 (no) | 2005-06-15 |
| NO20052914L NO20052914L (no) | 2005-07-19 |
Family
ID=9950253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052914A NO20052914L (no) | 2002-12-21 | 2005-06-15 | Terapeutiske forbindelser |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7462644B2 (no) |
| EP (1) | EP1572626A1 (no) |
| JP (2) | JP3786945B2 (no) |
| KR (1) | KR20050089065A (no) |
| CN (1) | CN1308291C (no) |
| AR (1) | AR042632A1 (no) |
| AU (1) | AU2003290309B2 (no) |
| BR (1) | BR0317458A (no) |
| CA (1) | CA2508851A1 (no) |
| CL (1) | CL2003002683A1 (no) |
| CO (1) | CO5580820A2 (no) |
| GB (1) | GB0229931D0 (no) |
| IS (1) | IS7946A (no) |
| MX (1) | MXPA05006812A (no) |
| NO (1) | NO20052914L (no) |
| PL (1) | PL377144A1 (no) |
| RU (1) | RU2005117792A (no) |
| TW (1) | TW200508180A (no) |
| UA (1) | UA80729C2 (no) |
| WO (1) | WO2004056748A1 (no) |
| ZA (1) | ZA200504730B (no) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| ES2307909T3 (es) | 2002-03-13 | 2008-12-01 | Janssen Pharmaceutica Nv | Derivados de piperazinil, piperidinil y morfolinil como nuevos inhidbidores de la histona deacetilasa. |
| JP4725945B2 (ja) | 2002-03-13 | 2011-07-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体 |
| WO2003076400A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | New inhibitors of histone deacetylase |
| WO2003076395A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| DK1517883T3 (da) | 2002-06-20 | 2008-05-26 | Astrazeneca Ab | Ortho-substituerede benzoesyrederivater til behandling af insulinresistens |
| NZ540612A (en) | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| EA010023B1 (ru) | 2003-07-14 | 2008-06-30 | Арена Фармасьютикалз, Инк. | Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма |
| NZ552865A (en) | 2004-07-28 | 2009-09-25 | Janssen Pharmaceutica Nv | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| US8138198B2 (en) | 2005-05-18 | 2012-03-20 | Angibaud Patrick Rene | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| ES2382876T3 (es) | 2005-05-31 | 2012-06-14 | Pfizer, Inc. | Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1 |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| US7888360B2 (en) | 2006-01-19 | 2011-02-15 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| EP1979326B1 (en) | 2006-01-19 | 2012-10-03 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| ES2327972T3 (es) | 2006-01-19 | 2009-11-05 | Janssen Pharmaceutica, N.V. | Derivados de aminofenil como nuevos inhibidores de histona deacetilasa. |
| JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
| CA2631874C (en) | 2006-01-19 | 2014-11-18 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| ES2376121T3 (es) | 2006-01-19 | 2012-03-09 | Janssen Pharmaceutica, N.V. | Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa. |
| HUE026057T2 (en) | 2006-05-09 | 2016-05-30 | Genzyme Corp | Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis |
| EP2594564B1 (en) | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| KR20150085139A (ko) | 2007-10-05 | 2015-07-22 | 젠자임 코포레이션 | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 |
| EP2320886B1 (en) | 2008-07-28 | 2017-06-28 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
| CN102316872B (zh) * | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
| EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| BR112013010157B1 (pt) | 2010-11-04 | 2020-02-04 | Albireo Ab | iinibidores do ibat, seus usos, e composição e combinações farmacêuticas |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| EP4445956A3 (en) | 2015-01-06 | 2024-12-04 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| PT3810581T (pt) | 2018-06-20 | 2025-03-05 | Albireo Ab | Modificações cristalinas de odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| AU2020218908B2 (en) | 2019-02-06 | 2025-01-23 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES3029063T3 (en) | 2019-12-04 | 2025-06-23 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| MX2022006731A (es) | 2019-12-04 | 2022-06-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar. |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| KR20230117393A (ko) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266121C (no) | ||||
| BE489216A (no) | 1948-06-05 | 1900-01-01 | ||
| US2928840A (en) * | 1958-11-26 | 1960-03-15 | Us Vitamin Pharm Corp | 3-(o-substituted phenyl) oxazolidinediones and process therefor |
| GB1081471A (en) | 1963-09-13 | 1967-08-31 | Stauffer Chemical Co | Glycol amide derivatives and use thereof in controlling weed growth |
| US3244398A (en) * | 1963-10-28 | 1966-04-05 | Scaramucci Domer | Composite seat ball valve |
| AT307640B (de) | 1970-06-18 | 1973-05-25 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen |
| BE792364A (fr) | 1971-12-06 | 1973-06-06 | Basf Ag | Derives de substitution du sulfonylglycolanilide |
| DE2349256C2 (de) | 1973-10-01 | 1985-08-01 | Basf Ag, 6700 Ludwigshafen | 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide |
| DE2828222A1 (de) | 1978-06-28 | 1980-01-10 | Bayer Ag | Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide |
| US4735959A (en) * | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
| US5216167A (en) * | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5312924A (en) * | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5210208A (en) * | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| DE69824433D1 (en) | 1997-08-28 | 2004-07-15 | Biovitrum Ab | Proteintyrosinphosphatase inhibitoren |
| US6410585B1 (en) * | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
| CA2305808A1 (en) * | 1997-10-02 | 1999-04-15 | Sankyo Company Limited | Amidocarboxylic acid derivatives |
| CA2309792A1 (en) | 1997-11-12 | 1999-05-20 | William C. Shakespeare | Novel signal transduction inhibitors, compositions containing them |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| AU760163B2 (en) | 1999-04-06 | 2003-05-08 | Sankyo Company Limited | Alpha-substituted carboxylic acid derivatives |
| AU3670900A (en) | 1999-04-08 | 2000-11-14 | Sankyo Company Limited | Substituted fused imidazole derivatives |
| JP2000351777A (ja) * | 1999-04-08 | 2000-12-19 | Sankyo Co Ltd | 置換縮合イミダゾール誘導体 |
| WO2000061584A1 (en) | 1999-04-14 | 2000-10-19 | The University Of British Columbia | IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| DK1177187T3 (da) | 1999-04-28 | 2007-10-15 | Sanofi Aventis Deutschland | Diarylsyrederivater som PPAR-receptorligander |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| JP2001261612A (ja) | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| WO2002044127A1 (fr) | 2000-11-29 | 2002-06-06 | Kyorin Pharmaceutical Co., Ltd. | Dérivés d'acide carboxylique substitué |
| JPWO2002044130A1 (ja) | 2000-11-29 | 2004-04-02 | 杏林製薬株式会社 | 置換カルボン酸誘導体 |
| EP1360172A1 (en) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| WO2002083616A1 (en) | 2001-04-10 | 2002-10-24 | Sankyo Company, Limited | α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| EP1517882A1 (en) | 2002-06-19 | 2005-03-30 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
| GB0314129D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2002
- 2002-12-21 GB GBGB0229931.1A patent/GB0229931D0/en not_active Ceased
-
2003
- 2003-12-10 TW TW092134839A patent/TW200508180A/zh unknown
- 2003-12-18 CL CL200302683A patent/CL2003002683A1/es unknown
- 2003-12-19 UA UAA200505596A patent/UA80729C2/uk unknown
- 2003-12-19 BR BR0317458-1A patent/BR0317458A/pt not_active IP Right Cessation
- 2003-12-19 MX MXPA05006812A patent/MXPA05006812A/es unknown
- 2003-12-19 US US10/499,893 patent/US7462644B2/en not_active Expired - Fee Related
- 2003-12-19 JP JP2004561668A patent/JP3786945B2/ja not_active Expired - Fee Related
- 2003-12-19 AR ARP030104752A patent/AR042632A1/es unknown
- 2003-12-19 WO PCT/GB2003/005602 patent/WO2004056748A1/en not_active Ceased
- 2003-12-19 PL PL377144A patent/PL377144A1/pl not_active Application Discontinuation
- 2003-12-19 RU RU2005117792/04A patent/RU2005117792A/ru not_active Application Discontinuation
- 2003-12-19 EP EP03782668A patent/EP1572626A1/en not_active Withdrawn
- 2003-12-19 CA CA002508851A patent/CA2508851A1/en not_active Abandoned
- 2003-12-19 AU AU2003290309A patent/AU2003290309B2/en not_active Ceased
- 2003-12-19 KR KR1020057011714A patent/KR20050089065A/ko not_active Withdrawn
- 2003-12-19 CN CNB2003801098952A patent/CN1308291C/zh not_active Expired - Fee Related
-
2005
- 2005-06-15 NO NO20052914A patent/NO20052914L/no not_active Application Discontinuation
- 2005-06-22 ZA ZA200504730A patent/ZA200504730B/en unknown
- 2005-07-19 CO CO05071340A patent/CO5580820A2/es not_active Application Discontinuation
- 2005-07-19 IS IS7946A patent/IS7946A/is unknown
- 2005-09-01 JP JP2005253346A patent/JP2006045240A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1572626A1 (en) | 2005-09-14 |
| CL2003002683A1 (es) | 2005-04-08 |
| BR0317458A (pt) | 2005-11-16 |
| ZA200504730B (en) | 2006-09-27 |
| CN1753862A (zh) | 2006-03-29 |
| JP2006045240A (ja) | 2006-02-16 |
| PL377144A1 (pl) | 2006-01-23 |
| AU2003290309B2 (en) | 2007-01-18 |
| MXPA05006812A (es) | 2005-09-08 |
| AR042632A1 (es) | 2005-06-29 |
| CO5580820A2 (es) | 2005-11-30 |
| IS7946A (is) | 2005-07-19 |
| KR20050089065A (ko) | 2005-09-07 |
| RU2005117792A (ru) | 2006-01-27 |
| UA80729C2 (en) | 2007-10-25 |
| AU2003290309A1 (en) | 2004-07-14 |
| CA2508851A1 (en) | 2004-07-08 |
| US20050131068A1 (en) | 2005-06-16 |
| JP2006511572A (ja) | 2006-04-06 |
| US7462644B2 (en) | 2008-12-09 |
| GB0229931D0 (en) | 2003-01-29 |
| NO20052914L (no) | 2005-07-19 |
| CN1308291C (zh) | 2007-04-04 |
| WO2004056748A1 (en) | 2004-07-08 |
| JP3786945B2 (ja) | 2006-06-21 |
| TW200508180A (en) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052914D0 (no) | Terapeutiske forbindelser | |
| DE60308332D1 (de) | Chinazolinverbindungen mit therapeutischem nutzen | |
| ATE368042T1 (de) | Cephemverbindungen | |
| IS7471A (is) | Ný efnasambönd | |
| NO20033203D0 (no) | Terapeutiske heterocykliske forbindelser | |
| IS7879A (is) | Ný efnasambönd | |
| IS7381A (is) | Efnasambönd | |
| DE60326590D1 (de) | Tend lamotrigin | |
| IS7414A (is) | Oxó-azabísýklísk efnasambönd | |
| NO20033205D0 (no) | Terapeutiske kromanforbindelser | |
| NO20045659L (no) | Forbindelser | |
| IS7827A (is) | Ný efnasambönd | |
| DK1597171T3 (da) | Terapeutisk mikroskum | |
| DK1553950T3 (da) | Terapeutisk behandling | |
| NO20050689L (no) | Terapeutisk anvendelse | |
| EP1478356A4 (en) | THERAPEUTIC COMPOUNDS | |
| DE60328488D1 (de) | Ng | |
| ITBO20020206A1 (it) | Vasca idromassaggio | |
| FR2839258B1 (fr) | Deambulateur-siege | |
| SE0203348D0 (sv) | Novel compounds | |
| NO20043433L (no) | Fremgangsmate | |
| SE0203826D0 (sv) | Therapeutic agents | |
| SE0200450D0 (sv) | Therapeutic agents | |
| SE0100007D0 (sv) | Therapeutic compounds | |
| SE0100009D0 (sv) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |